Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Fields of Study & Subjects
Publication details
- Journal / source
- PubMed Central
- Volume
- 8
- Issue
- 1
- Pages
- otag008–otag008
- Publication date
- 1 January 2026
- Language
- EN